Panelists from FDA, Genentech, and Minaris discussed raw material risk, supplier oversight, and at-risk release strategies for advanced therapies at the PDA/FDA Joint Regulatory Conference.
|Articles|June 15, 2019
- BioPharm International-06-15-2019
- Volume 2019 eBook
- Issue 2
The Importance of Single-Use Components for Bioprocessing
Author(s)Feliza Mirasol
Simple components help maintain physical integrity throughout a bioprocess setup, and single-use components play a role in ensuring a closed system for aseptic processing.
Advertisement
Simple components such as tubing and gaskets are important for maintaining the physical integrity of a bioprocess setup. Single-use versions of these components offer convenience as well as play a role in maintaining aseptic processes, thus helping to ensure that the bioprocess setup is a closed system. In a discussion with Ray Baldwin, business development manager for Biopure, a Watson-Marlow Fluid Technology Group (WMFTG) company, BioPharm Internationalexplores single-use components and the role they play in bioprocessing.
Read
Article Details
BioPharm International
eBook: Single-Use Systems 2019
Vol. 32
June 2019
Pages: 18–19
Citation
When referring to this article, please cite it as F. Mirasol, "The Importance of Single-Use Components for Bioprocessing," BioPharm International Single-Use Systems eBook (June 2019).
Articles in this issue
over 7 years ago
New Strategies for Managing Single-Use Componentsover 7 years ago
Buffers Benefit from Single-Use Systemsover 7 years ago
Thinking Flexibly in Biomanufacturingover 7 years ago
Single-Use Bioreactors Unwrap Commercial Manufacturing OptionsAdvertisement
Related to this article
Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Phio's PH-762 posted a 70% response rate in skin cancer, supporting its FDA briefing package for a planned phase 2b trial.
Samsung Biologics signed a $262 million contract manufacturing agreement with an undisclosed European pharmaceutical company, extending production commitments through 2033 and lifting the CDMO's cumulative contract value past $21.9 billion.
Aptar Pharma's Nanopharm business will lead inhaled formulation development and device assessment for ACT-101, Aceso Therapeutics' antisense oligonucleotide candidate designed to correct CFTR protein function in cystic fibrosis patients carrying the F508del mutation.
Advertisement
Advertisement